ARTICLE | Preclinical News
Tet2 disruption improves Kymriah efficacy
May 30, 2018 9:36 PM UTC
In a Nature study, researchers at the University of Pennsylvania identified a patient with an enhanced response to CAR T therapy Kymriah tisagenlecleucel, and suggested targeting the epigenome by inhibiting Tet2 could improve the efficacy of CAR T therapies.
The paper's authors include CAR T pioneer Carl June, whose research led to the development of Kymriah, which Novartis AG (NYSE:NVS; SIX:NOVN) licensed from UPenn...